HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.

Abstract
Transfusion-associated iron overload could be an important risk factor in myeloablative hematopoietic stem cell transplantation. However, few studies have evaluated the effect of iron overload in reduced-intensity stem cell transplantation (RIST). We evaluated 38 patients with myeloid malignancies, 16 with and 22 without iron overload, who received RIST. We used pretransplant serum ferritin as a marker of iron overload. There was a positive correlation between the number of transfused packed red blood cells and pretransplant serum ferritin levels (21.5 units and 1,578.7 microg/l in the iron overload group vs. 12 units and 739.3 microg/l in the iron non-overload group; p <0.01). Engraftment day and chimerism analysis were not affected by iron overload (p = 0.71 and 0.47, respectively). There were no differences in treatment-related mortality (p = 0.94), veno-occlusive disease (p = 0.99), acute and chronic graft versus host disease (p = 0.58 and 0.99, respectively) according to iron overload. There was a significant difference in disease-free and overall survival (35.8 and 27% in the iron overload group vs. 80.6 and 54.6% in the iron non-overload group; p = 0.01 and 0.03, respectively). We conclude that transfusion-associated iron overload is an adverse risk factor in RIST for myeloid malignancies. The clinical outcomes according to iron overload in RIST were different in myeloablative hematopoietic stem cell transplantation. A serial follow-up of serum ferritin level and judicious iron chelation therapy will be needed to manage the side effect of iron overload in RIST and improve transplantation outcomes.
AuthorsYu Ri Kim, Jin Seok Kim, June-Won Cheong, Jae Woo Song, Yoo Hong Min
JournalActa haematologica (Acta Haematol) Vol. 120 Issue 3 Pg. 182-9 ( 2008) ISSN: 1421-9662 [Electronic] Switzerland
PMID19129689 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2008 S. Karger AG, Basel.
Chemical References
  • Iron Chelating Agents
  • Ferritins
Topics
  • Adolescent
  • Adult
  • Erythrocyte Transfusion
  • Female
  • Ferritins (blood)
  • Hematologic Neoplasms (blood, mortality, therapy)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Iron Chelating Agents (therapeutic use)
  • Iron Overload (blood, drug therapy, etiology, mortality)
  • Male
  • Middle Aged
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: